首頁 > 市場調查報告書 > 醫療設備

體外診斷生技設備

市場調查報告書

商品編碼

1623515

血液培養檢測市場：區域、範圍和預測

Blood Culture Tests Market By Method, By Product, By Technology, By Application, By End-User, By Geography Scope And Forecast

出版日期: 2024年11月11日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

血液培養檢測的市場規模及預測

預計2024年血液培養檢測市場價值約為53.9億美元，到2031年將達到99.7億美元，2024年至2031年的複合年增長率約為8.81%。血液培養是一種診斷程序，用於檢測血液中是否存在細菌、真菌和其他微生物，這可能表明存在全身性感染，如菌血症或敗血症。當患者出現嚴重感染的跡象，例如發燒、發冷、心跳過快或精神錯亂時，就會進行血液培養。血液培養對於診斷可能擴散至血液的感染至關重要。

血液培養測試對於治療嚴重感染和確定治療方案至關重要。血液培養有助於預防敗血症等併發症，如果不及時治療，可能會危及生命。

全球醫療保健支出的增加，加上醫護人員和病患對傳染病的認識提高，增加了對血液培養檢測的需求。

全球血液培養檢測市場動態

影響全球血液培養檢測市場的關鍵市場動態

關鍵推動因素

血流感染發生率高：

血流感染發生率高：血流感染是全世界發病和死亡的主要原因。據估計，美國每年發生超過 60 萬例血液感染，造成巨大的醫療費用。

對快速診斷技術的需求不斷增加：

為了提供適當的抗生素治療，越來越需要更快、更準確地診斷血流感染。這促使了先進的血液培養技術的開發和實施。

傳染病發生率高：

敗血症、肺炎和腦膜炎等傳染病的全球負擔不斷增加。例如，2017年，敗血症估計影響了全球4,890萬人，並導致1,100萬人死亡。

老年人口不斷增加：

老年人的免疫系統較弱，更容易感染傳染病。預計到 2050 年，全球 65 歲及以上人口將從 2020 年的 7.27 億增加到 15 億。

主要問題

解釋的複雜性：

由於需要區分污染物和臨床顯著的病原體，因此血液培養結果的解釋很困難。這種複雜性增加了對熟練專業人員的依賴，這可能會阻礙市場成長。調查發現，相當一部分實驗室（79%）認為病原體鑑定對於準確解釋很重要。

漫長的過程：

傳統的血液培養測試通常需要幾天才能提供結果，從而延遲診斷和治療。美國的平均測試週轉時間為兩到三天，漫長的等待時間可能會對患者的治療結果產生負面影響。

自動化系統成本高：

自動化血液培養系統所需的初始投資較高，從 50,000 美元到 100,000 美元不等，這使得小型醫療機構難以採用這些技術。

污染風險：

血液培養污染仍然是一個嚴重的問題，會導致假陽性結果，使診斷和治療決策變得複雜。受污染的培養基會導致不必要的治療並增加醫療成本。

主要趨勢：

技術進步：

自動化血液培養系統的創新正在提高檢測效率和準確性。由於檢測技術的進步，自動化領域預計將以最快的速度成長。

傳染病發生率增加：

醫療相關性感染呈上升趨勢，美國大約每 31 名住院患者中就有 1 名感染。

增加醫療支出：

全球醫療保健支出的增加推動了先進診斷解決方案的採用，包括血液培養檢測。這一趨勢正在推動更有效的測試方法的開發和實施。

聚焦在敗血症診斷：

血液培養檢測在診斷敗血症的重要性日益得到認可，在美國，每年約有 170 萬人患有敗血症，這進一步推動了市場需求。

The Blood Culture Tests Market was valued at approximately USD 5.39 Billion in 2024 and is anticipated to reach USD 9.97 Billion by 2031, growing at a CAGR of about 8.81% from 2024 to 2031. A blood culture test is a diagnostic procedure used to detect the presence of bacteria, fungi, or other microorganisms in the bloodstream, which can indicate a systemic infection such as bacteremia or sepsis. Blood cultures are ordered when patients exhibit symptoms of severe infection, such as fever, chills, rapid heart rate, or confusion. They are crucial for diagnosing infections that may have spread to the bloodstream.

Blood culture tests are vital for managing serious infections and guiding treatment decisions. They help prevent complications such as sepsis, which can be life-threatening if not addressed promptly.

Growing worldwide healthcare expenditure, combined with improved knowledge of infectious diseases among healthcare providers and patients, has increased demand for blood culture testing.

Global Blood Culture Tests Market Dynamics

The key market dynamics that are shaping the global blood culture tests market include:

Key Drivers

High Incidence of Bloodstream Infections:

Bloodstream infections are a major cause of morbidity and mortality worldwide. In the United States, it is estimated that there are over 600,000 cases of bloodstream infections annually, resulting in significant healthcare costs.

Growing Demand for Rapid Diagnostic Techniques:

There is an increasing need for faster and more accurate diagnosis of bloodstream infections to guide appropriate antibiotic therapy. This has driven the development and adoption of advanced blood culture technologies.

High Prevalence of Infectious Diseases:

The global burden of infectious diseases, such as sepsis, pneumonia, and meningitis, has been rising. For example, in 2017, sepsis was estimated to affect 48.9 million people and result in 11 million deaths worldwide.

Rising Geriatric Population:

The elderly population is more susceptible to infections due to weakened immune systems. The global population aged 65 and above is projected to increase from 727 million in 2020 to 1.5 billion in 2050.

Key Challenges:

Complexity in Interpretation:

Interpreting blood culture results can be challenging due to the need to distinguish between contaminants and clinically significant pathogens. This complexity increases reliance on skilled professionals, which can hinder market growth. Studies indicate that a significant percentage of laboratories (79%) find organism identity crucial for accurate interpretation .

Time-Consuming Process:

Traditional blood culture tests often take several days to yield results, delaying diagnosis and treatment. This prolonged wait can negatively impact patient outcomes, as the average turnaround time in the U.S. is typically 2-3 days .

High Costs of Automated Systems:

The initial investment for automated blood culture systems can be substantial, ranging from $50,000 to $100,000, making it difficult for smaller healthcare facilities to adopt these technologies .

Contamination Risks:

Blood culture contamination remains a significant issue, leading to false-positive results that complicate diagnosis and treatment decisions. Contaminated cultures can result in unnecessary treatments and increased healthcare costs.

Key Trends:

Technological Advancements:

Innovations in automated blood culture systems are improving the efficiency and accuracy of tests. The automated segment is anticipated to grow at the fastest pace, driven by advancements in testing technology.

Rising Incidence of Infections:

The prevalence of healthcare-associated infections continues to rise, with approximately 1 in 31 hospitalized patients in the U.S. suffering from such infections, driving the demand for blood culture tests.

Increased Healthcare Expenditure:

Rising global healthcare expenditure is facilitating the adoption of advanced diagnostic solutions, including blood culture tests. This trend supports the development and implementation of more efficient testing methods.

Focus on Sepsis Diagnostics:

There is a growing recognition of the importance of blood culture tests in diagnosing sepsis, which affects approximately 1.7 million individuals annually in the U.S., further propelling market demand.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Blood Culture Systems Market Regional Analysis

Here is a more detailed regional analysis of the global blood culture systems market:

North America:

North America accounted for 35% of the global blood culture tests market revenue in 2023, making it the largest market globally. This dominance is attributed to a well-established healthcare infrastructure and advanced diagnostic capabilities.

The region experiences a significant burden of bloodstream infections, with approximately 250,000 cases occurring annually in the U.S. alone. This high incidence drives demand for effective diagnostic tools like blood culture tests.

Technological Advancements: North America is at the forefront of technological innovations in blood culture testing, including automated systems that reduce turnaround times and improve accuracy. The presence of major players such as Becton, Dickinson and Company and bioMerieux enhances market growth through continuous product development.

Government-funded programs and initiatives aimed at improving infection control and management contribute to market growth. For example, funding from agencies like BARDA supports the development of advanced diagnostic technologies, which are crucial for timely infection diagnosis.

Asia Pacific

The Asia Pacific region is expected to exhibit the highest compound annual growth rate (CAGR) of 8.32% from 2023 to 2033, reflecting a significant demand for blood culture tests driven by increasing infection rates and healthcare advancements.

The region faces a growing incidence of bloodstream infections, including sepsis and hospital-associated infections. For instance, the World Health Organization estimates that around 49 million people suffer from sepsis globally each year, with a substantial number of cases occurring in Asia Pacific.

Countries like China and India are investing heavily in healthcare infrastructure and diagnostics, which enhances the capacity for early diagnosis and treatment of infectious diseases. This investment is crucial as the region aims to improve healthcare outcomes .

Increased awareness among healthcare professionals about the importance of accurate diagnosis of bloodstream infections is leading to greater acceptance and utilization of blood culture tests in clinical settings.

Global Blood Culture Systems Market: Segmentation Analysis

The Global Blood Culture Systems Market is Segmented on the Basis of Method, Product, Technology, Application, End-User And Geography.

Blood Culture Tests Market, By Method

Conventional/Manual Methods
Automated Methods

Based on Method, the market is segmented into Conventional/Manual Methods and Automated Methods. The conventional/manual methods dominate over automated methods. In 2023, conventional/manual blood culture methods held approximately 64.78% of the market share, making them the most widely used technique for blood culture testing. This dominance is attributed to their long-standing familiarity and acceptance among laboratory operators.

Blood Culture Tests Market, By Product

Consumables
Instruments
Software & Services

Based on Product, the market is segmented into Consumables, Instruments and Software & Services. The consumables segment accounted for the largest share of the blood culture tests market in 2023, with a revenue of approximately USD 3.5 Billion. This segment includes essential items such as blood culture media, reagents, assay kits, and other supplies necessary for conducting blood culture tests.

Blood Culture Tests Market, By Technology

Culture-based Technology
Molecular Technologies
Proteomics Technology

Based on Technology, the market is segmented into Culture-based Technology, Molecular Technologies and Proteomics Technology. The culture-based technology segment accounted for the largest share of the blood culture tests market in 2023, driven by its established effectiveness in detecting bacteria and fungi in blood samples. This segment remains the gold standard for diagnosing bloodstream infections.

Blood Culture Tests Market, By Application

Bacteremia
Fungemia
Mycobacterial Detection

Based on Application, the market is segmented into Bacteremia, Fungemia and Mycobacterial Detection. The bacteremia segment holds the largest share of the blood culture tests market, primarily due to the high prevalence of bacterial infections in bloodstream cases. Bacteremia is a critical condition that requires prompt diagnosis and treatment, making blood culture tests essential.

Blood Culture Tests Market, By End-User

Hospital Laboratories
Reference Laboratories
Academic Research Laboratories
Other

Based on End-User, the market is segmented into Hospital Laboratories, Reference Laboratories, Academic Research Laboratories and Other. Hospital laboratories accounted for more than 45% of the blood culture tests market share in 2023. This significant share is due to the high volume of tests conducted in hospitals, particularly for patients with infectious diseases.

Blood Culture Tests Market, By Geography

North America
Europe
Asia Pacific
Latin America
Middle East and Africa
On the basis of Geography, the market is classified into North America, Europe, Asia Pacific, and the Rest of the World. Hospital laboratories accounted for more than 45% of the blood culture tests market share in 2023. This significant share is due to the high volume of tests conducted in hospitals, particularly for patients with infectious diseases.

Key Players

The "Global Blood Culture Tests Market" study report will provide valuable insight with an emphasis on the global market including some of the major players of the industry are
Thermo Fisher Scientific, Inc., T2 Biosystems, Inc., Cepheid, Inc., Roche Diagnostics, Beckman Coulter, BioMerieux SA, IRIDICA, Bruker Corporation, Nanosphere, Inc., Becton Dickinson and Company, Abbott Laboratories, Siemens Healthineers AG, Streck, Omega Diagnostics Group PLC, Qiagen N.V., BD Diagnostics, & F. Hoffmann-La Roche Ltd, among others.

Our market analysis offers detailed information on major players wherein our analysts provide insight into the financial statements of all the major players, product portfolio, product benchmarking, and SWOT analysis. The competitive landscape section also includes market share analysis, key development strategies, recent developments, and market ranking analysis of the above-mentioned players globally.

Blood Culture Tests Recent Developments
In February 2023, Cepheid announced the launch of its new Xpert(R) Blood Culture Identification (BCID) test, which provides rapid identification of pathogens directly from positive blood cultures. This test significantly reduces the time required to identify infectious agents, enhancing the speed of diagnosis and treatment.
In March 2023, Roche Diagnostics launched its new cobas(R) 8800 System for blood culture testing, which enhances the detection of pathogens in blood samples. This automated system is designed to provide faster results and improve workflow efficiency in clinical laboratories.

1 INTRODUCTION OF GLOBAL BLOOD CULTURE TESTS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL BLOOD CULTURE TESTS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL BLOOD CULTURE TESTS MARKET, BY PRODUCT

5.1 Overview
5.2 Instruments
5.3 Blood Culture Media
5.4 Assay Kits & Reagents
5.5 Blood Culture Accessories

6 GLOBAL BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY

6.1 Overview
6.2 Polymerase Chain Reaction (PCR)
6.3 Microarrays
6.4 Culture-Based Technology
6.5 Proteomics Technology

7 GLOBAL BLOOD CULTURE TESTS MARKET, BY APPLICATION

7.1 Overview
7.2 Bacteremia
7.3 Fungemia
7.4 Mycobacterial Detection

8 GLOBAL BLOOD CULTURE TESTS MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East And Africa

9 GLOBAL BLOOD CULTURE TESTS MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Biomerieux SA
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Nanosphere, Inc.
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Becton, Dickinson and Company
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Roche Diagnostics
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Thermo Fisher Scientific, Inc.
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Bruker Corporation
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Cepheid (Danaher Corporation)
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments